Potentiation of retinoic acid-induced differentiation of human acute promyelocytic leukemia NB4 cells by butyric acid, tributyrin, and hexamethylene bisacetamide

Oncology Research

Volumn 10, Issue 2, 1998, Pages 75-84

  Taimi, Mohammed ^a   Chen, Zi Xing ^b   Breitman, Theodore R ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SOOCHOW UNIVERSITY   (China)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Butyrates; Cell differentiation; Drug combinations; Drug synergism; Retinoic acid

Indexed keywords

ACETAMIDE DERIVATIVE; ANTINEOPLASTIC AGENT; BUTYRIC ACID; BUTYRIC ACID DERIVATIVE; HEXAMETHYLENEBISACETAMIDE; RETINOIC ACID; TRIACYLGLYCEROL; TRIBUTYRIN;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM; PATHOLOGY; PROMYELOCYTIC LEUKEMIA;

ACETAMIDES; ANTINEOPLASTIC AGENTS; BUTYRIC ACID; BUTYRIC ACIDS; CELL DIFFERENTIATION; DRUG SYNERGISM; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; TRETINOIN; TRIGLYCERIDES; TUMOR CELLS, CULTURED;

EID: 0031608848     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Castaigne, S.; Chomienne, C.; Daniel, M. T.; Ballerini, P.; Berger, R.; Fenaux, P.; Degos, L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76:1704-1709; 1990.
2. Warrell, R. P., Jr.; Frankel, S. R.; Miller, W. H., Jr.; Scheinberg, D. A.; Itri, L. M.; Hittelman, W. N.; Vyas, R.; Andreeff, M.; Tafuri, A.; Jakubowski, A.; Gabrilove, J.; Gordon, M. S.; Dmitrovsky, E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med. 324:1385-1393; 1991.
3. Chen, Z. X.; Xue, Y. Q.; Zhang, R.; Tao, R. F.; Xia, X. M.; Li, C.; Wang, W.; Zu, W. Y.; Yao, X. Z.; Ling, B. J. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 78:1413-1419; 1991.
4. Muindi, J.; Frankel, S. R.; Miller, W. H., Jr.; Jakubowski, A.; Scheinberg, D. A.; Young, C. W.; Dmitrovsky, E.; Warrell, R. P., Jr. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood 79:299-303; 1992.
5. Delva, L.; Cornic, M.; Balitrand, N.; Guidez, F.; Miclea, J. M.; Delmer, A.; Teillet, F.; Fenaux, P.; Castaigne, S.; Degos, L.; Chomienne, C. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 82:2175-2181; 1993.
6. Adamson, P. C. Pharmacokinetics of all-trans-retinoic acid: Clinical implications in acute promyelocytic leukemia. Semin. Hematol. 31:14-17; 1994.
7. Cornic, M.; Delva, L.; Guidez, F.; Balitrand, N.; Degos, L.; Chomienne, C. Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. Cancer Res. 52:3329-3334; 1992.
8. Fiorella, P. D.; Napoli, J. L. Expression of cellular retinoic acid binding protein (CRABP) in Escherichia coli. Characterization and evidence that holo-CRABP is a substrate in retinoic acid metabolism. J. Biol. Chem. 266:16572-16579; 1991.
9. Napoli, J. L.; Posch, K. P.; Fiorella, P. D.; Boerman, M. H. E. M. Physiological occurrence, biosynthesis and metabolism of retinoic acid: Evidence for roles of cellular retinol-binding protein (CRBP) and cellular retinoic acid-binding protein (CRABP) in the pathway of retinoic acid homeostasis. Biomed. Pharmacother. 45:131-143; 1991.
10. Boylan, J. F.; Gudas, L. J. The level of CRABP-I expression influences the amounts and types of all-trans-retinoic acid metabolites in F9 teratocarcinoma stem cells. J. Biol. Chem. 267:21486-21491; 1992.
11. Stoner, C. M.; Gudas, L. J. Mouse cellular retinoic acid binding protein: Cloning, complementary DNA sequence, and messenger RNA expression during the retinoic acid-induced differentiation of F9 wild type and RA-3-10 mutant teratocarcinoma cells. Cancer Res. 49:1497-1504; 1989.
12. Boylan, J. F.; Gudas, L. J. Overexpression of the cellular retinoic acid binding protein-I (CRABP-I) results in a reduction in differentiation-specific gene expression in F9 teratocarcinoma cells. J. Cell Biol. 112:965-979; 1991.
13. Siegenthaler, G.; Tomatis, I.; Chatellard-Gruaz, D.; Jaconi, S.; Eriksson, U.; Saurai, J. H. Expression of CRABP-I and -II in human epidermal cells. Alteration of relative protein amounts is linked to the state of differentiation. Biochem. J. 287:383-389; 1992.
14. Breitman, T. R.; Keene, B. R. Growth and differentiation of the human promyelocytic cell line, HL-60, in a defined medium. In: Sirbasku, D. A.; Sato, G. H.; Pardee, A. B., eds. Growth of cells in hormonally defined media. Cold Spring Harbor Conferences on Cell Proliferation. New York: Cold Spring Harbor Laboratory Press; 1982:691-702.
15. Breitman, T. R.; He, R.-Y. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60. Cancer Res. 50:6268-6273; 1990.
16. Olsson, I. L.; Breitman, T. R.; Gallo, R. C. Priming of human myeloid leukemic cell lines HL-60 and U-937 with retinoic acid for differentiation effects of cyclic adenosine 3′:5′-monophosphate-inducing agents and a T-lymphocyte-derived differentiation factor. Cancer Res. 42:3928-3933; 1982.
17. Chen, Z. X.; Breitman, T. R. Tributyrin: A prodrug of butyric acid for potential clinical application in differentiation therapy. Cancer Res. 54:3494-3499; 1994.
18. Brown, G.; Bunce, C. M.; Rowlands, D. C.; Williams, G. R. All-trans retinoic acid and 1α,25-dihydroxyvitamin D3 co-operate to promote differentiation of the human promyeloid leukemia cell line HL60 to monocytes. Leukemia 8:806-815; 1994.
19. Lanotte, M.; Martin-Thouvenin, V.; Najman, S.; Balerini, P.; Valensi, F.; Berger, R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77:1080-1086; 1991.
20. Castaigne, S.; Balitrand, N.; de The, H.; Dejean, A.; Degos, L.; Chomienne, C. A PML/retinoic acid receptor α fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood 79:3110-3115; 1992.
21. Taimi, M.; Breitman, T. R. Growth, differentiation, and death of retinoic acid-treated human acute promyelocytic leukemia NB4 cells. Exp. Cell Res. 230:69-75; 1997.
22. Del Giudice, R. A.; Gardella, R. S. Mycoplasma infection of cell culture: Effects, incidence, and detection. In: Patterson, M. K., ed. In vitro monograph No. 5. Use and standardization of vertebrate cell cultures. Gaitherburg, MD: Tissue Culture Association; 1984: 104-115.
23. Breitman, T. R. Growth and differentiation of human myeloid leukemia cell line HL60. Methods Enzymol. 190:118-130; 1990.
24. Barker, H. A. Separation, identification, and estimation of lower fatty acids. Methods Enzymol. 3:372-382; 1957.
25. He, R.-Y.; Breitman, T. R. Retinoic acid inhibits sodium butyrate-induced monocytic differentiation of HL60 cells while synergistically inducing granulocytoid differentiation. Eur. J. Haematol. 46: 93-100; 1991.
26. Agadir, A.; Comic, M.; Lefebvre, P.; Gourmel, B.; Balitrand, N.; Degos, L.; Chomienne, C. Differential uptake of all-trans retinoic acid by acute promyelocytic leukemic cells: Evidence for its role in retinoic acid efficacy. Leukemia 9:139-145; 1995.
27. Taimi, M.; Breitman, T. R. N-4-hydroxyphenylretinamide enhances retinoic acid-induced differentiation and retinoylation of proteins in the human acute promyelocytic leukemia cell line, NB4, by a mechanism that may involve inhibition of retinoic acid catabolism. Biochem. Biophys. Res. Commun. 232:432-436; 1997.
28. Egorin, M. J.; Snyder, S. W.; Cohen, A. S.; Zuhowski, E. G.; Subramanyam, B.; Callery, P. S. Metabolism of hexamethylene bisacetamide and its metabolites in leukemic cells. Cancer Res. 48:1712-1716; 1988.
29. Leong, K. W.; Bosco, J. J.; Teh, A. Advantage of induction therapy with all trans retinoic acid in acute promyelocytic leukaemia in a country with limited transfusion resources: A Malaysian experience. Eur. J. Haematol. 53:237-241; 1994.
30. Takeshita, A.; Sakamaki, H.; Miyawaki, S.; Kobayashi, T.; Kuriyama, K.; Yamada, O.; Oh, H.; Takenaka, T.; Asou, N.; Ohno, R. Significant reduction of medical costs by differentiation therapy with all-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. The Japan Adult Leukemia Study Group. Cancer 76:602-608; 1995.
31. Adamson, P. C.; Boylan, J. F.; Balis, F. M.; Murphy, R. F.; Godwin, K. A.; Gudas, L. J.; Poplack, D. G. Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. Cancer Res. 53:472-476; 1993.
32. Cornic, M.; Delva, L.; Castaigne, S.; Lefebvre, P.; Balitrand, N.; Degos, L.; Chomienne, C. In vitro all-trans retinoic acid (ATRA) sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia. Leukemia 8:914-917; 1994.
33. Boylan, J. F.; Lufkin, T.; Achkar, C. C.; Taneja, R.; Chambon, P.; Gudas, L. J. Targeted disruption of retinoic acid receptor α (RAR α) and RAR gamma results in receptor-specific alterations in retinoic acid-mediated differentiation and retinoic acid metabolism. Mol. Cell. Biol. 15:843-851; 1995.
34. Breitman, T. R.; Chen, Z. X.; Takahashi, N. Potential applications of cytodifferentiation therapy in hematologic malignancies. Semin. Hematol. 31:18-25; 1994.
35. Ruchaud, S.; Duprez, E.; Gendron, M. C.; Houge, G.; Genieser, H. G.; Jastorff, B.; Doskeland, S. O.; Lanotte, M. Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line. Proc. Natl. Acad. Sci. USA 91:8428-8432; 1994.
36. Chen, A.; Licht, J. D.; Wu, Y.; Hellinger, N.; Scher, W.; Waxman, S. Retinoic acid is required for and potentiates differentiation of acute promyelocytic leukemia cells by nonretinoid agents. Blood 84:2122-2129; 1994.
37. Gianni, M.; Terao, M.; Norio, P.; Barbui, T.; Rambaldi, A.; Garattini, E. All-trans retinoic acid and cyclic adenosine monophosphate cooperate in the expression of leukocyte alkaline phosphatase in acute promyelocytic leukemia cells. Blood 85:3619-3635; 1995.
38. Lefebvre, P.; Thomas, G.; Gourmel, B.; Agadir, A.; Castaigne, S.; Dreux, C.; Degos, L.; Chomienne, C. Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Leukemia 5:1054-1058; 1991.
39. Muindi, J. R. F.; Frankel, S. R.; Huselton, C.; DeGrazia, F.; Garland, W. A.; Young, C. W.; Warrell, R. P., Jr. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res. 52:2138-2142; 1992.
40. Yuan, Z.; Eiseman, J.; Plaisance, K.; Sentz, D.; Bigora, S.; Fossler, M.; Young, D.; Egorin, M. Plasma pharmacokinetics (PK) of butyrate after administration of tributyrin and Na butyrate to mice and rats. Proc. Am. Assoc. Cancer Res. 35:429; 1994.
41. Young, C. W.; Fanucchi, M. P.; Walsh, T. D.; Baltzer, L.; Yaldaei, S.; Stevens, Y.-W.; Gordon, C.; Tong, W.; Rifkind, R. A.; Marks, P. A. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals. Cancer Res. 48:7304-7309; 1988.
42. Rigas, J. R.; Francis, P. A.; Muindi, J. R. F.; Kris, M. G.; Huselton, C.; DeGrazia, F.; Orazem, J. P.; Young, C. W.; Warrell, R. P., Jr. Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. J. Natl. Cancer Inst. 85:1921-1926; 1993.
43. Miller, V. A.; Rigas, J. R.; Muindi, J. R. F.; Tong, W. P.; Venkatraman, E.; Kris, M. G.; Warrell, R. P., Jr. Modulation of all-trans retinoic acid pharmacokinetics by liarozole. Cancer Chemother. Pharmacol. 34:522-526; 1994.
44. Bryson, H. M.; Wagslaff, A. J. Liarozole. Drugs Aging 9:478-484; 1996.
45. Schwartz, E. L.; Hallam, S.; Gallagher, R. E.; Wiernik, P. H. Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. Biochem. Pharmacol. 50:923-928; 1995.
46. Lee, J. S.; Newman, R. A.; Lippman, S. M.; Fossella, F. V.; Calayag, M.; Raber, M. N.; Krakoff, I. H.; Hong, W. K. Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors. J. Clin. Oncol. 13:1501-1508; 1995.
47. Conley, B. A.; Egorin, M. J.; Tait, N.; Rosen, D. M.; Sausville, E. A.; Dover, G.; Fram, R. J.; Van Echo, D. A. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin. Cancer Res. 4:629-634; 1998.